{
  "pmcid": "8404630",
  "sha256": "22592cd5034ed66962ac5ab8a7a104815af4cece01ee4fc41b09ac01464627a2",
  "timestamp_utc": "2025-11-10T00:09:17.068984+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.111977373339897,
    "reading_ease": 13.94775454992623,
    "word_count": 214
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on Genetic Polymorphisms Affecting Antithrombotic Therapy in Bangladeshi CVD Patients"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Randomisation was achieved through computer-generated sequences"
      },
      "Participants": {
        "score": 2,
        "evidence": "1,000 CVD patients (782 males, 218 females) at United Hospital, Dhaka, Bangladesh"
      },
      "Intervention": {
        "score": 2,
        "evidence": "treated with clopidogrel and/or aspirin"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aims to assess the prevalence of genetic polymorphisms CYP2C19*2, CYP2C19*17, and ITGB3 in Bangladeshi cardiovascular disease (CVD) patients"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the prevalence of genetic polymorphisms, measured over the study period"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was achieved through computer-generated sequences, and allocation was concealed using sealed envelopes"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not applicable"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "1,000 CVD patients (782 males, 218 females) at United Hospital, Dhaka, Bangladesh, from March 2017 to November 2018"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Among clopidogrel-treated patients, 64.1% exhibited CYP2C19*2 polymorphism"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "64.1% exhibited CYP2C19*2 polymorphism, and 22.7% exhibited CYP2C19*17 polymorphism"
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: Not provided."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 17,
    "max_score": 25
  }
}